Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of BIA 3-202 and Levodopa/Benserazide in Healthy Volunteers
NCT02763852Phase 1Completed
- Sponsor
- BIAL
- Start
- Apr 2001
- Primary completion
- Jul 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nebicapone in Parkinson's disease (PD) (6 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration at 24 hours, Area under the plasma concentration time curve extrapolated to infinity at 24 hours and 1 more. Started Apr 2001; status: completed.
02
Drugs
nebicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02763852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763852.